The study highlights how shelters can experience infectious disease outbreaks and how they can be prevented. Continue Reading »

The findings of a clinical trial may help fill a healthcare gap for the 1% to 5% of adults worldwide who experience long COVID.  Continue Reading »

A proposed rule would add COVID-19 vaccines and therapeutics to the Countermeasures Injury Compensation Program. Continue Reading »

People with long COVID who experienced more symptoms are less active and have lower heart rate variability and a higher resting heart rate. Continue Reading »

Ocular symptoms like blurred vision and difficulty reading affect up to 35% of people with long COVID, but standard eye exams can’t detect these issues. Continue Reading »

A study finds that the antiviral drug is safe to prescribe in children with COVID-19 who are at least 6 years old. Continue Reading »

Among Medicare beneficiaries, healthcare use and costs spiked sharply in the first week after infection, then dropped substantially over time. Continue Reading »

The reduction in transfers to emergency departments is driven by increased testing and case detection and faster flu antiviral initiation rather than smaller outbreaks. Continue Reading »

Social media can give health professionals a real-time understanding of how people feel about a major scientific advancement such as a vaccine. Continue Reading »

A new study finds that benefits of mRNA technology are substantial and serious adverse events rare.  Continue Reading »

The analysis looks at medical records of 2.5 million patients across the VA health system. Continue Reading »

Machine learning helps scientists analyze complex datasets, uncovering subtle patterns that are key to vaccine development.  Continue Reading »

Reduced productivity may be up to three times more common in those with long COVID. Continue Reading »

The flu outbreak at Joint Base San Antonio Lackland Air Force Base has risen to 275 cases. Continue Reading »

Having no ACIP quorum needs be addressed, because fall respiratory vaccine recommendations have to come from somewhere. Continue Reading »

In the United States, COVID-19, pandemic H1N1 flu, and West Nile were most costly in terms of health and related expenses. Continue Reading »

A separate study finds that a booster dose reduced the risk of symptomatic COVID requiring a healthcare visit by 59%. Continue Reading »

Two new studies find that the benefits of the booster outweigh the risks.  Continue Reading »

The research provides a greater understanding of factors that might contribute to persistent symptoms. Continue Reading »

People with long COVID are more likely to experience angina and myocardial infarction, according to a national survey. Continue Reading »

This report presents a description of COVID-19 vaccine coverage in the EU/EEA between 1 August 2025 and 27 March 2026, with some variation in reporting dates between countries. Continue Reading »

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 27 June - 3 July 2026, and includes updates on Ebola, West Nile Virus infections, Crimean-Congo haemorrhagic fever, expert deployment, Middle East respiratory syndrome (MERS), Vibrio, and ... Continue Reading »

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 26 June 2026, and includes updates on Ebola, West Nile Virus infections, Crimean-Congo haemorrhagic fever, Influenza A(H9N2), cholera, mpox, dengue, expert deployment, travel-associated chikungunya virus ... Continue Reading »

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line ... Continue Reading »

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 23-29 May 2026, and includes updates on SARS-CoV-2 variant classification, Ebola, Middle East respiratory syndrome (MERS), mpox, West Nile virus, Salmonella, Dermatophilus congolensis and malaria. Continue Reading »

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 23-29 May 2026, and includes updates on Ebola, hantavirus, cholera, and West Nile virus. Continue Reading »

The European Centre for Disease Prevention and Control (ECDC) hosted the annual meeting of the European Respiratory Viruses Network (ERVI-Net) in Vienna, Austria, on 20–22 May 2026, which brought together nearly 80 representatives from EU/EEA and accession countries. Continue Reading »

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-22 May 2026, and includes updates on hantavirus, chikungunya, Ebola disease outbreak, avian influenza, measles, and an overview of respiratory virus epidemiology in the EU/EEA. Continue Reading »

Respiratory virus activity remains low overall across the EU/EEA: RSV: activity has returned to baseline inter-seasonal levels. Influenza: activity remains at baseline inter-seasonal levels. SARS-CoV-2: activity remains at very low levels overall. Continue Reading »

This handbook provides an updated overview of commonly used laboratory protocols for the characterisation of SARS-CoV-2, provided by the AURORAE consortium. Continue Reading »